STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.
Read more at prnewswire.com
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Provided By PR Newswire – Last update: